Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial

Autor: Jayne M Morgan, David Cohen, Anne C Seagrove, Alan Watkins, John Williams, M Fasih Alam, Ian Shaw, Shaji Sebastian, Ian D. Arnott, Frances Rapport, Simon Travis, Mike Hilton, Hayley A Hutchings, John C. Mansfield, Clare Clement, A Barney Hawthorne, Laith Alrubaiy, Aida U Jawhari, John N. Gordon, Mirella Longo

Publikováno v: Williams, J, Alrubaiy, L, Arnott, I, Clement, C, Cohen, D, Gordon, J, Hawthorn, B, Hilton, M, Hutchings, H, Jawhari, A, Longo, M, Mansfield, J, Morgan, J, Rapport, F, Seagrove, A, Sebastian, S, Shaw, I, Travis, S & Wakins, A 2016, ' Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT) : a mixed methods, open-label, pragmatic randomised trial ', Lancet Gastroenterology and Hepatology, vol. 1, no. 1, pp. 15-24 . https://doi.org/10.1016/S2468-1253(16)30003-6
The Lancet. Gastroenterology & Hepatology

BackgroundInfliximab and ciclosporin are of similar efficacy in treating acute severe ulcerative colitis, but there has been no comparative evaluation of their relative clinical effectiveness and cost-effectiveness.MethodsIn this mixed methods, open-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e346084a4e855681d4aa8cedeb5cc224